AR111182A1 - Composición farmacéutica de análogos de deutetrabenazina, su preparación y uso - Google Patents
Composición farmacéutica de análogos de deutetrabenazina, su preparación y usoInfo
- Publication number
- AR111182A1 AR111182A1 ARP180100611A ARP180100611A AR111182A1 AR 111182 A1 AR111182 A1 AR 111182A1 AR P180100611 A ARP180100611 A AR P180100611A AR P180100611 A ARP180100611 A AR P180100611A AR 111182 A1 AR111182 A1 AR 111182A1
- Authority
- AR
- Argentina
- Prior art keywords
- deutetrabenazine
- pharmaceutical composition
- formula
- compound
- determination made
- Prior art date
Links
- MKJIEFSOBYUXJB-VFJJUKLQSA-N (3r,11br)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one Chemical group C1CN2C[C@@H](CC(C)C)C(=O)C[C@@H]2C2=C1C=C(OC([2H])([2H])[2H])C(OC([2H])([2H])[2H])=C2 MKJIEFSOBYUXJB-VFJJUKLQSA-N 0.000 title abstract 21
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 7
- 229950005031 deutetrabenazine Drugs 0.000 abstract 19
- 238000000034 method Methods 0.000 abstract 10
- 150000001875 compounds Chemical class 0.000 abstract 5
- 238000004128 high performance liquid chromatography Methods 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 4
- 208000000269 Hyperkinesis Diseases 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 229940088679 drug related substance Drugs 0.000 abstract 2
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 239000006194 liquid suspension Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Pens And Brushes (AREA)
- Machine Translation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471484P | 2017-03-15 | 2017-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111182A1 true AR111182A1 (es) | 2019-06-12 |
Family
ID=61873991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100611A AR111182A1 (es) | 2017-03-15 | 2018-03-15 | Composición farmacéutica de análogos de deutetrabenazina, su preparación y uso |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11813232B2 (enExample) |
| EP (1) | EP3596077A1 (enExample) |
| JP (3) | JP7608050B2 (enExample) |
| KR (2) | KR20200003791A (enExample) |
| CN (1) | CN110709398A (enExample) |
| AR (1) | AR111182A1 (enExample) |
| AU (2) | AU2018236336B2 (enExample) |
| BR (1) | BR112019018966A2 (enExample) |
| CA (1) | CA3056612A1 (enExample) |
| CL (1) | CL2019002629A1 (enExample) |
| CO (1) | CO2019011271A2 (enExample) |
| EA (1) | EA201992168A1 (enExample) |
| IL (1) | IL269132A (enExample) |
| MX (1) | MX2019010913A (enExample) |
| PE (1) | PE20191819A1 (enExample) |
| SG (1) | SG11201908477QA (enExample) |
| TW (1) | TWI772382B (enExample) |
| UA (1) | UA127052C2 (enExample) |
| WO (1) | WO2018170214A1 (enExample) |
| ZA (1) | ZA201906326B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113395966A (zh) * | 2018-12-13 | 2021-09-14 | 奥斯佩克斯医药公司 | 用于治疗脑瘫中的运动障碍的方法 |
| WO2020165807A1 (en) * | 2019-02-14 | 2020-08-20 | Dr. Reddy's Laboratories Limited | Solid forms of deutetrabenazine and process for the preparation thereof |
| PE20230852A1 (es) * | 2020-06-10 | 2023-05-29 | Auspex Pharmaceuticals Inc | Formas farmaceuticas osmoticas que comprenden deutetrabenazina y metodos de uso de las mismas |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007317242B2 (en) | 2006-11-08 | 2013-08-01 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
| EP3345905B1 (en) | 2008-09-18 | 2021-09-01 | Auspex Pharmaceuticals, Inc. | Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2 |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012081031A1 (en) * | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
| JP6362601B2 (ja) * | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
| US9550780B2 (en) * | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2930744A1 (en) * | 2013-12-03 | 2015-06-11 | Auspex Pharmaceuticals, Inc. | Methods of manufacturing benzoquinoline compounds |
| IL288712B2 (en) | 2015-03-06 | 2024-01-01 | Auspex Pharmaceuticals Inc | Methods for the treatment of abnormal involuntary movement disorders |
-
2018
- 2018-03-15 WO PCT/US2018/022562 patent/WO2018170214A1/en not_active Ceased
- 2018-03-15 CN CN201880018609.8A patent/CN110709398A/zh active Pending
- 2018-03-15 PE PE2019001871A patent/PE20191819A1/es unknown
- 2018-03-15 JP JP2019550774A patent/JP7608050B2/ja active Active
- 2018-03-15 UA UAA201910309A patent/UA127052C2/uk unknown
- 2018-03-15 AR ARP180100611A patent/AR111182A1/es unknown
- 2018-03-15 SG SG11201908477Q patent/SG11201908477QA/en unknown
- 2018-03-15 MX MX2019010913A patent/MX2019010913A/es unknown
- 2018-03-15 EP EP18715393.7A patent/EP3596077A1/en active Pending
- 2018-03-15 US US15/922,329 patent/US11813232B2/en active Active
- 2018-03-15 AU AU2018236336A patent/AU2018236336B2/en active Active
- 2018-03-15 KR KR1020197030354A patent/KR20200003791A/ko not_active Ceased
- 2018-03-15 TW TW107108832A patent/TWI772382B/zh active
- 2018-03-15 CA CA3056612A patent/CA3056612A1/en active Pending
- 2018-03-15 EA EA201992168A patent/EA201992168A1/ru unknown
- 2018-03-15 KR KR1020227043234A patent/KR20230003308A/ko not_active Ceased
- 2018-03-15 BR BR112019018966-1A patent/BR112019018966A2/pt not_active Application Discontinuation
-
2019
- 2019-09-04 IL IL26913219A patent/IL269132A/en unknown
- 2019-09-13 CL CL2019002629A patent/CL2019002629A1/es unknown
- 2019-09-25 ZA ZA2019/06326A patent/ZA201906326B/en unknown
- 2019-09-25 US US16/582,362 patent/US11179386B2/en active Active
- 2019-10-10 CO CONC2019/0011271A patent/CO2019011271A2/es unknown
-
2021
- 2021-10-21 US US17/507,037 patent/US20220040170A1/en active Pending
- 2021-11-30 US US17/537,663 patent/US20220088006A1/en not_active Abandoned
-
2022
- 2022-05-18 AU AU2022203369A patent/AU2022203369B2/en active Active
- 2022-11-04 JP JP2022177578A patent/JP2023010754A/ja active Pending
-
2024
- 2024-01-30 JP JP2024011974A patent/JP7631572B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11364252B2 (en) | System and method for diagnosis and treatment | |
| US20230265193A1 (en) | Pd-1 signal inhibitor combination therapy | |
| EP3184519A1 (en) | ACID-ADDITION SALT OF Trk-INHIBITING COMPOUND | |
| Gros et al. | Pharmacological regulators of autophagy and their link with modulators of lupus disease | |
| BR112021024674A2 (pt) | Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| MA37206B1 (fr) | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| CL2018003178A1 (es) | Composición farmacéutica | |
| CY1124104T1 (el) | Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη | |
| Feng et al. | Basil polysaccharide inhibits hypoxia-induced hepatocellular carcinoma metastasis and progression through suppression of HIF-1α-mediated epithelial-mesenchymal transition | |
| AR111182A1 (es) | Composición farmacéutica de análogos de deutetrabenazina, su preparación y uso | |
| AR070465A1 (es) | Compuestos biciclicos con contenido de nitrogeno activos en condiciones de dolor cronicas | |
| AR112536A1 (es) | Métodos para reducir la formación de partículas y composiciones elaboradas a través de los mismos | |
| TR200401436T4 (tr) | Monotiyogliserol, L-sistem veya tiyoglikolik asitle birlikte pemetrexed içeren farmasötik bileşim | |
| CN111712245A (zh) | 用于肝细胞癌的治疗剂 | |
| AR095562A1 (es) | Cristales de laquinimod sódico y proceso mejorado para su fabricación | |
| EA201991023A1 (ru) | Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту | |
| MX2021007393A (es) | Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf. | |
| WO2019031898A3 (ko) | 약학 조성물 및 이의 제조방법 | |
| Schnichels et al. | Trichostatin A induces cell death at the concentration recommended to differentiate the RGC-5 cell line | |
| CN110057942B (zh) | 一种利伐沙班及其制剂的有关物质的检测方法 | |
| AR048501A1 (es) | Compuesto de benzoazabicicloheptano dimerico, composicion farmaceutica que lo comprende y su uso para prepararla | |
| PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
| ECSP003538A (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo [2.2.2.] oct-3-ilamina y sus composiciones farmaceuticas | |
| MX2024013176A (es) | Nuevos anticuerpos anti proteina 3 similar a la angiopoyetina (angptl3) adecuados para composiciones de concentracion alta y administracion subcutanea | |
| BR112013026755A2 (pt) | derivados da acadesina, produtos e composições que os compreendem, as respectivas utilizações terapêuticas e os respectivos processos de síntese |